Pharmicell Co., Ltd. (005690.KS)
KRW 11620.0
(10.14%)
KRW 11620.0
(10.14%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.02 Billion KRW | -82.02% |
| 2022 | 16.84 Billion KRW | -2.34% |
| 2021 | 17.24 Billion KRW | 462.62% |
| 2020 | 3.06 Billion KRW | -0.47% |
| 2019 | 3.08 Billion KRW | 2.67% |
| 2018 | 3 Billion KRW | 657.58% |
| 2017 | 396 Million KRW | 0.0% |
| 2016 | - KRW | -100.0% |
| 2015 | 3.01 Billion KRW | -66.52% |
| 2014 | 8.99 Billion KRW | 1.71% |
| 2013 | 8.84 Billion KRW | -67.46% |
| 2012 | 27.16 Billion KRW | 78.54% |
| 2011 | 15.21 Billion KRW | 9.52% |
| 2010 | 13.89 Billion KRW | 59.51% |
| 2009 | 8.71 Billion KRW | 15.31% |
| 2008 | 7.55 Billion KRW | -74.85% |
| 2007 | 30.02 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 646.32 Million KRW | -79.66% |
| 2024 Q1 | 3.17 Billion KRW | 4.97% |
| 2023 Q1 | 17.22 Billion KRW | 2.29% |
| 2023 Q4 | 3.02 Billion KRW | -33.79% |
| 2023 FY | 3.02 Billion KRW | -82.02% |
| 2023 Q2 | 15.88 Billion KRW | -7.78% |
| 2023 Q3 | 4.57 Billion KRW | -71.22% |
| 2022 Q2 | 18.78 Billion KRW | 3.91% |
| 2022 FY | 16.84 Billion KRW | -2.34% |
| 2022 Q4 | 16.84 Billion KRW | -14.49% |
| 2022 Q3 | 19.69 Billion KRW | 4.84% |
| 2022 Q1 | 18.08 Billion KRW | 4.84% |
| 2021 Q1 | 3.22 Billion KRW | 5.18% |
| 2021 Q4 | 17.24 Billion KRW | 4.69% |
| 2021 Q2 | 15.69 Billion KRW | 386.75% |
| 2021 Q3 | 16.47 Billion KRW | 4.97% |
| 2021 FY | 17.24 Billion KRW | 462.62% |
| 2020 FY | 3.06 Billion KRW | -0.47% |
| 2020 Q1 | 3.19 Billion KRW | 3.6% |
| 2020 Q3 | 3.1 Billion KRW | -1.34% |
| 2020 Q4 | 3.06 Billion KRW | -1.32% |
| 2020 Q2 | 3.14 Billion KRW | -1.31% |
| 2019 Q4 | 3.08 Billion KRW | -1.2% |
| 2019 FY | 3.08 Billion KRW | 2.67% |
| 2019 Q3 | 3.11 Billion KRW | -1.23% |
| 2019 Q2 | 3.15 Billion KRW | 5.22% |
| 2019 Q1 | 3 Billion KRW | 0.0% |
| 2018 Q4 | 3 Billion KRW | 0.0% |
| 2018 Q2 | 3 Billion KRW | 6.38% |
| 2018 FY | 3 Billion KRW | 657.58% |
| 2018 Q1 | 2.82 Billion KRW | 612.17% |
| 2018 Q3 | 3 Billion KRW | 0.0% |
| 2017 Q1 | - KRW | 0.0% |
| 2017 Q4 | 396 Million KRW | 0.0% |
| 2017 FY | 396 Million KRW | 0.0% |
| 2017 Q3 | - KRW | 0.0% |
| 2017 Q2 | - KRW | 0.0% |
| 2016 Q2 | 3.11 Billion KRW | 1.79% |
| 2016 Q4 | - KRW | 0.0% |
| 2016 FY | - KRW | -100.0% |
| 2016 Q3 | - KRW | -100.0% |
| 2016 Q1 | 3.06 Billion KRW | 1.77% |
| 2015 Q2 | 2.9 Billion KRW | -68.12% |
| 2015 FY | 3.01 Billion KRW | -66.52% |
| 2015 Q4 | 3.01 Billion KRW | 1.76% |
| 2015 Q3 | 2.95 Billion KRW | 1.75% |
| 2015 Q1 | 9.12 Billion KRW | 1.43% |
| 2014 FY | 8.99 Billion KRW | 1.71% |
| 2014 Q3 | 11.86 Billion KRW | 1.04% |
| 2014 Q2 | 11.74 Billion KRW | 52.53% |
| 2014 Q1 | 7.69 Billion KRW | -12.92% |
| 2014 Q4 | 8.99 Billion KRW | -24.22% |
| 2013 Q3 | 23.37 Billion KRW | 1.06% |
| 2013 Q4 | 8.84 Billion KRW | -62.17% |
| 2013 Q2 | 23.12 Billion KRW | -6.81% |
| 2013 Q1 | 24.81 Billion KRW | -8.65% |
| 2013 FY | 8.84 Billion KRW | -67.46% |
| 2012 FY | 27.16 Billion KRW | 78.54% |
| 2012 Q4 | 27.16 Billion KRW | 0.0% |
| 2012 Q1 | 15.03 Billion KRW | 0.0% |
| 2011 Q3 | 11.17 Billion KRW | -46.86% |
| 2011 Q2 | 21.02 Billion KRW | 6.32% |
| 2011 Q1 | 19.77 Billion KRW | 42.31% |
| 2011 FY | 15.21 Billion KRW | 9.52% |
| 2010 Q1 | 8.74 Billion KRW | 0.39% |
| 2010 Q4 | 13.89 Billion KRW | 40.25% |
| 2010 FY | 13.89 Billion KRW | 59.51% |
| 2010 Q2 | 8.77 Billion KRW | 0.4% |
| 2010 Q3 | 9.9 Billion KRW | 12.85% |
| 2009 Q3 | 9.67 Billion KRW | 69.21% |
| 2009 Q2 | 5.71 Billion KRW | 0.86% |
| 2009 Q1 | 5.67 Billion KRW | -24.94% |
| 2009 FY | 8.71 Billion KRW | 15.31% |
| 2009 Q4 | 8.71 Billion KRW | -9.99% |
| 2008 Q1 | 30.14 Billion KRW | 0.38% |
| 2008 Q4 | 7.55 Billion KRW | -74.44% |
| 2008 FY | 7.55 Billion KRW | -74.85% |
| 2008 Q2 | 29.88 Billion KRW | -0.85% |
| 2008 Q3 | 29.55 Billion KRW | -1.1% |
| 2007 FY | 30.02 Billion KRW | 0.0% |
| 2007 Q4 | 30.02 Billion KRW | 2.86% |
| 2007 Q3 | 29.19 Billion KRW | 2.4% |
| 2007 Q2 | 28.51 Billion KRW | 0.46% |
| 2007 Q1 | 28.37 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | 3.03 Billion KRW | 0.394% |
| Green Cross Holdings Corporation | 1280.16 Billion KRW | 99.763% |
| Green Cross Holdings Corporation | 724.02 Billion KRW | 99.582% |
| Green Cross Corporation | 724.02 Billion KRW | 99.582% |
| GeneOne Life Science, Inc. | 17.15 Billion KRW | 82.355% |
| Celltrion, Inc. | 1890.42 Billion KRW | 99.84% |
| Samsung Biologics Co.,Ltd. | 1909.33 Billion KRW | 99.841% |
| SK bioscience Co.,Ltd. | 20.57 Billion KRW | 85.283% |
| SK Biopharmaceuticals Co., Ltd. | 178.05 Billion KRW | 98.3% |
| Prestige BioPharma Limited | 89.66 Billion KRW | 96.623% |